Aurinia Pharmaceuticals (AUPH) Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AUPH shares.
View AUPH analyst ratings or view top-rated stocks.

4 brokerages have issued twelve-month price targets for Aurinia Pharmaceuticals' stock. Their AUPH share price forecasts range from $12.00 to $14.00. On average, they predict the company's share price to reach $13.00 in the next twelve months. This suggests a possible upside of 45.1% from the stock's current price.
View analysts price targets for AUPH or view top-rated stocks among Wall Street analysts.

Aurinia Pharmaceuticals' stock was trading at $4.32 on January 1st, 2023. Since then, AUPH shares have increased by 107.4% and is now trading at $8.96.
View the best growth stocks for 2023 here.

Aurinia Pharmaceuticals saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 15,520,000 shares, a drop of 7.1% from the April 30th total of 16,710,000 shares. Based on an average trading volume of 3,110,000 shares, the days-to-cover ratio is currently 5.0 days.
View Aurinia Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our AUPH earnings forecast.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) announced its quarterly earnings results on Thursday, May, 4th. The biotechnology company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. The biotechnology company had revenue of $34.41 million for the quarter, compared to the consensus estimate of $28.12 million. Aurinia Pharmaceuticals had a negative trailing twelve-month return on equity of 23.56% and a negative net margin of 65.90%. The business's quarterly revenue was up 59.1% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.27) EPS.

ETFs with the largest weight of Aurinia Pharmaceuticals (NASDAQ:AUPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), ProShares Ultra Nasdaq Biotechnology (BIB),

Aurinia Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $135.00 million-$155.00 million, compared to the consensus revenue estimate of $142.68 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY).

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

Aurinia Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.53%), Armistice Capital LLC (2.92%), State Street Corp (1.80%), Renaissance Technologies LLC (1.11%), Geode Capital Management LLC (0.93%) and Balyasny Asset Management L.P. (0.92%). Insiders that own company stock include David RW Jayne, George M Milne Jr, Jill Leversage, Joseph M Miller, Joseph P Hagan, Matthew Maxwell Donley, Michael Robert Martin, Neil Solomons, Peter Greenleaf, Robert Bindert Huizinga and Stephen P Robertson.
View institutional ownership trends.

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AUPH stock can currently be purchased for approximately $8.96.

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a market capitalization of $1.28 billion and generates $134.03 million in revenue each year. The biotechnology company earns $-108,180,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis.

The company employs 300 workers across the globe.

Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The official website for the company is www.auriniapharma.com. The biotechnology company can be reached via phone at 250-708-4272, via email at ir@auriniapharma.com, or via fax at 250-744-2498.